Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.
Reck M, Blais N, Juhasz E, Gorbunova V, Jones CM, Urban L, Orlov S, Barlesi F, Kio E, Keilholz U, Qin Q, Qian J, Nickner C, Dziubinski J, Xiong H, Mittapalli RK, Dunbar M, Ansell P, He L, McKee M, Giranda V, Ramalingam SS. Reck M, et al. Among authors: dunbar m. J Thorac Oncol. 2017 Jul;12(7):1098-1108. doi: 10.1016/j.jtho.2017.04.010. Epub 2017 Apr 29. J Thorac Oncol. 2017. PMID: 28461256 Free article. Clinical Trial.
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
Mehta MP, Wang D, Wang F, Kleinberg L, Brade A, Robins HI, Turaka A, Leahy T, Medina D, Xiong H, Mostafa NM, Dunbar M, Zhu M, Qian J, Holen K, Giranda V, Curran WJ. Mehta MP, et al. Among authors: dunbar m. J Neurooncol. 2015 Apr;122(2):409-17. doi: 10.1007/s11060-015-1733-1. Epub 2015 Feb 15. J Neurooncol. 2015. PMID: 25682091 Clinical Trial.
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML. van der Biessen DAJ, et al. Among authors: dunbar m. Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8. Invest New Drugs. 2018. PMID: 29313279 Free PMC article. Clinical Trial.
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Byers LA, Bentsion D, Gans S, Penkov K, Son C, Sibille A, Owonikoko TK, Groen HJM, Gay CM, Fujimoto J, de Groot P, Dunbar M, Kang K, He L, Sehgal V, Glasgow J, Bach BA, Ellis PM. Byers LA, et al. Among authors: dunbar m. Clin Cancer Res. 2021 Jul 15;27(14):3884-3895. doi: 10.1158/1078-0432.CCR-20-4259. Epub 2021 May 4. Clin Cancer Res. 2021. PMID: 33947690 Clinical Trial.
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
Ramalingam SS, Novello S, Guclu SZ, Bentsion D, Zvirbule Z, Szilasi M, Bernabe R, Syrigos K, Byers LA, Clingan P, Bar J, Vokes EE, Govindan R, Dunbar M, Ansell P, He L, Huang X, Sehgal V, Glasgow J, Bach BA, Mazieres J. Ramalingam SS, et al. Among authors: dunbar m. J Clin Oncol. 2021 Nov 10;39(32):3633-3644. doi: 10.1200/JCO.20.03318. Epub 2021 Aug 26. J Clin Oncol. 2021. PMID: 34436928 Free PMC article. Clinical Trial.
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
Clarke JM, Patel JD, Robert F, Kio EA, Thara E, Ross Camidge D, Dunbar M, Nuthalapati S, Dinh MH, Bach BA. Clarke JM, et al. Among authors: dunbar m. Lung Cancer. 2021 Nov;161:180-188. doi: 10.1016/j.lungcan.2021.09.004. Epub 2021 Sep 17. Lung Cancer. 2021. PMID: 34607210 Free article. Clinical Trial.
Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Govindan R, et al. Among authors: dunbar m. Clin Lung Cancer. 2022 May;23(3):214-225. doi: 10.1016/j.cllc.2022.01.005. Epub 2022 Feb 4. Clin Lung Cancer. 2022. PMID: 35331641 Free article. Clinical Trial.
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Camidge DR, et al. Among authors: dunbar m. J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Epub 2022 Oct 26. J Clin Oncol. 2023. PMID: 36288547 Free PMC article. Clinical Trial.
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K. Camidge DR, et al. Among authors: dunbar m. JTO Clin Res Rep. 2021 Dec 4;3(1):100262. doi: 10.1016/j.jtocrr.2021.100262. eCollection 2022 Jan. JTO Clin Res Rep. 2021. PMID: 35005654 Free PMC article.
615 results